Phase 1 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to give informed consent and follow the study requirements
• People of any gender
• People aged 18 to 75 years (for Phase Ia of the study) or aged 18 and older (for Phase Ib of the study)
• People with an expected survival time of at least 3 months
• People with a confirmed diagnosis of multiple myeloma or another blood cancer that has not responded to standard treatments, or for which no standard treatment currently exists
• People whose disease has measurable signs that meet the protocol's definitions (confirm with trial site)
• People in good general physical condition, rated 0 or 1 on a standard performance scale (meaning able to carry out normal daily activities with little or no restriction)
• People whose side effects from previous cancer treatments have largely resolved to a mild level or better
• People with no serious heart function problems, and a heart pumping strength of 50% or above
• People whose organ function meets the levels required by the study (confirm with trial site)
• People whose blood clotting levels fall within acceptable ranges as defined by the protocol
• Women of childbearing age who test negative for pregnancy within 7 days before starting treatment and who are not breastfeeding; all participants, regardless of gender, must use adequate barrier contraception during treatment and for 6 months after treatment ends

Who may not be able to join:

• People whose cancer has spread to the central nervous system
• People who have received chemotherapy, biological therapy, immunotherapy, or similar treatments within 4 weeks before the first dose, or within 5 half-lives of the relevant medication
• People with a history of serious heart disease
• People with certain heart rhythm problems, including prolonged QT interval, complete left bundle branch block, or third-degree heart block
• People with active autoimmune diseases or active inflammatory conditions
• People who have been diagnosed with another cancer within the past 5 years
• People with high blood pressure that remains poorly controlled despite taking two blood pressure medications
• People with poorly controlled blood sugar levels
• People who have had a serious blood clot event requiring treatment within the past 6 months
• People with significant lung disease (rated Grade 3 or higher on a standard severity scale), or a history of a type of lung scarring condition that required steroid treatment
• People with significant nerve damage in the hands or feet (Grade 3 or higher, or persistent Grade 2 with pain)
• People with a known allergy to certain types of antibody-based medicines or to any ingredient in the study drug BL-M24D1
• People who have previously had an organ transplant or a bone marrow transplant using cells from a donor
• People who test positive for HIV, or who have active tuberculosis, active hepatitis B, or active hepatitis C
• People who have had an active infection requiring treatment throughout the body within 4 weeks before the first dose
• People who have had fluid build-up in the chest, abdomen, pelvis, or around the heart requiring drainage or causing symptoms within 4 weeks before the first dose
• People who have had significant bleeding or a clear tendency to bleed within 4 weeks before the first dose
• People who have participated in another clinical trial within 4 weeks before the first dose
• Women who are pregnant or breastfeeding
• People who have received a live vaccine within 30 days before the first dose
• People whom the study doctor considers unsuitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.